Results 161 to 170 of about 2,882,240 (203)

Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. [PDF]

Clin Infect Dis, 2021
Lu H, Cole SR, Westreich D, Hudgens MG, Adimora AA, Althoff KN, Silverberg MJ, Buchacz K, Li J, Edwards JK, Rebeiro PF, Lima VD, Marconi VC, Sterling TR, Horberg MA, Gill MJ, Kitahata MM, Eron JJ, Moore RD.   +18 more
europepmc   +1 more source

First Reported Case of Integrase Strand Transfer Inhibitor Resistance in Suriname: Unusual Drug Resistance Mutations Following Exposure to Dolutegravir. [PDF]

Viruses
Sno RC, Culbard G, Adhin MR.
europepmc   +1 more source

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk. [PDF]

Trials
Nyein PP, Haskelberg H, Martinello M, Lowe M, Goodman-Meza D, Avihingsanon A, Kelleher AD, Rodgers A, Schutte AE, Nnakelu EC, Byakwaga H, Trevillyan J, Losso M, Kumarasamy N, Azwa RISR, Kaplan R, Clifton B, Arnott C, Dharan NJ, Petoumenos K, Matthews GV.   +20 more
europepmc   +1 more source

Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study. [PDF]

BMC Infect Dis
Squillace N, Ricci ED, Orofino G, Forcina G, Albini L, Menzaghi B, De Socio GV, Piconi S, Maggi P, Madeddu G, Pellicanò GF, Sarchi E, Celesia BM, Lagi F, Salomoni E, Di Biagio A, Bonfanti P.   +16 more
europepmc   +1 more source

Association of Integrase Strand Transfer Inhibitor-Based Antiretroviral Therapy With Blood Pressure and Sustained Hypertension in People With Human Immunodeficiency Virus. [PDF]

Am J Hypertens
Siddiqui M, Burkholder GA, Judd E, Wang Z, Colantonio LD, Ghazi L, Shimbo D, Willig AL, Overton ET, Oparil S, Levitan EB, Heath SL, Muntner P.   +12 more
europepmc   +1 more source

Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy. [PDF]

Pan Afr Med J
Hurbans N, Naidoo P.
europepmc   +1 more source

The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions. [PDF]

BMC Infect Dis
Maman O, Ahmad WA, Perzon O, Mahlab-Guri K, Elbirt D, Elinav H.   +5 more
europepmc   +1 more source

Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis. [PDF]

HIV Med
Rashid I, Unger NR, Willis C, Dhippayom T, Ramgopal M, Sherman EM, Yared N, Safran R, Swiatlo E, Weinberg AR, Navadeh S, Schmutz HW, Chaiyakunapruk N.   +12 more
europepmc   +1 more source

Elucidating the Molecular Determinants of the Binding Modes of a Third-Generation HIV-1 Integrase Strand Transfer Inhibitor: The Importance of Side Chain and Solvent Reorganization. [PDF]

Viruses
Sun Q, Biswas A, Lyumkis D, Levy R, Deng N.   +4 more
europepmc   +1 more source